Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

BPMC Blueprint Medicines Corporation

-1.93 (-2.02%)
Feb 29 2024 - Closed
Delayed by 15 minutes


Draw Mode:

Volume 733,947
Bid Price 91.00
Ask Price 99.41
News -
Day High 98.82


52 Week Range


Day Low 92.95
Company Name Stock Ticker Symbol Market Type
Blueprint Medicines Corporation BPMC NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
-1.93 -2.02% 93.52 20:00:00
Open Price Low Price High Price Close Price Prev Close
98.82 92.95 98.82 93.52 95.45
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
10,949 733,947 $ 95.24 $ 69,899,857 - 40.30 - 101.00
Last Trade Time Type Quantity Stock Price Currency
18:56:14 6 $ 93.52 USD

Blueprint Medicines (BPMC) Options Flow Summary

Overall Flow


Net Premium


Calls / Puts


Buys / Sells




Sweeps Ratio


Blueprint Medicines Corporation Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
5.69B 60.79M - 204.04M -557.52M -9.17 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Blueprint Medicines News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No BPMC Message Board. Create One! See More Posts on BPMC Message Board See More Message Board Posts

Historical BPMC Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week87.00101.0080.4293.141,356,1206.527.49%
1 Month79.33101.0072.2485.431,003,08814.1917.89%
3 Months72.94101.0071.9784.85905,06920.5828.21%
6 Months49.00101.0043.8971.27765,33244.5290.86%
1 Year40.53101.0040.3063.15709,12252.99130.74%
3 Years99.40117.8637.8267.36634,856-5.88-5.92%
5 Years78.75125.6137.8271.58595,12414.7718.76%

Blueprint Medicines Description

Blueprint Medicines Corp is a biopharmaceutical company. It is focused on improving the lives of patients with diseases driven by abnormal kinase activation. The company has developed a small molecule drug pipeline in cancer and a rare genetic disease. Its drug candidates BLU-285, which targets KIT Exon 17 mutants and PDGFRa D842V, abnormally active receptor tyrosine kinase mutants that are drivers of cancer and proliferative disorders. Its other drug candidate is BLU 554 FOR Advanced Hepatocellular Carcinoma, and BLU-667 for Ret Mutations, Fusions, and Predicted Resistant Mutants.

Your Recent History

Delayed Upgrade Clock